IL284679A - Multifunctional chimeric proteins and their use - Google Patents
Multifunctional chimeric proteins and their useInfo
- Publication number
- IL284679A IL284679A IL284679A IL28467921A IL284679A IL 284679 A IL284679 A IL 284679A IL 284679 A IL284679 A IL 284679A IL 28467921 A IL28467921 A IL 28467921A IL 284679 A IL284679 A IL 284679A
- Authority
- IL
- Israel
- Prior art keywords
- fusion proteins
- functional fusion
- functional
- proteins
- fusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789212P | 2019-01-07 | 2019-01-07 | |
| PCT/US2020/012624 WO2020146423A1 (en) | 2019-01-07 | 2020-01-07 | Multi-functional fusion proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL284679A true IL284679A (en) | 2021-08-31 |
Family
ID=71521906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284679A IL284679A (en) | 2019-01-07 | 2021-07-07 | Multifunctional chimeric proteins and their use |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12497439B2 (https=) |
| EP (1) | EP3908664A4 (https=) |
| JP (1) | JP7587505B2 (https=) |
| KR (1) | KR20220025698A (https=) |
| CN (1) | CN113518823B (https=) |
| AU (1) | AU2020207265B2 (https=) |
| BR (1) | BR112021013415A2 (https=) |
| CA (1) | CA3125748A1 (https=) |
| IL (1) | IL284679A (https=) |
| MX (1) | MX2021008207A (https=) |
| SG (1) | SG11202107454UA (https=) |
| WO (1) | WO2020146423A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2769769C2 (ru) | 2017-01-05 | 2022-04-05 | Кахр Медикал Лтд. | СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| CN110536693B (zh) | 2017-01-05 | 2023-12-22 | 卡尔医学有限公司 | Pd1-41bbl融合蛋白及使用其的方法 |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| EP3820887A4 (en) | 2018-07-11 | 2022-04-20 | KAHR Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| EP3908664A4 (en) | 2019-01-07 | 2023-01-25 | Thomas Jefferson University | MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
| CN116261567A (zh) * | 2020-07-03 | 2023-06-13 | 纽约市哥伦比亚大学理事会 | 多功能性正交蛋白嵌合体 |
| US20240076346A1 (en) * | 2021-01-13 | 2024-03-07 | Kahr Medical Ltd. | Type i membrane proteins heterodimers and methods of use thereof |
| WO2022188129A1 (zh) * | 2021-03-12 | 2022-09-15 | 利时雨 | 广谱趋化因子受体抑制剂增强新冠肺炎病毒感染的细胞免疫的分子机制及在其药物防治中的应用 |
| AU2023253516A1 (en) * | 2022-04-15 | 2024-11-21 | Imbiologics Corp. | Fusion protein platform with improved half-life |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030220482A1 (en) | 2000-02-03 | 2003-11-27 | Ziwei Huang | Novel peptide antagonist of CXCR4 derived from the N-terminus of the viral chemokine vMIP-II |
| WO2002022687A2 (en) | 2000-09-15 | 2002-03-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Viral chemokine-tumur antigen fusion proteins |
| CA2448109A1 (en) | 2001-05-25 | 2002-12-05 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| DE102009047243A1 (de) * | 2009-11-27 | 2011-06-01 | Orgentec Diagnostika Gmbh | Monospezifische Polypeptidreagenzien |
| WO2014121085A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Pd-l1 and pd-l2-based fusion proteins and uses thereof |
| CA2920377A1 (en) * | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| JP2018516969A (ja) * | 2015-06-12 | 2018-06-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Pd−1およびcxcr4シグナル伝達経路の組合せ遮断による癌の処置 |
| CA3004804A1 (en) * | 2015-11-17 | 2017-05-26 | Jiangsu Hengrui Medicine Co., Ltd. | Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| JP6732915B2 (ja) | 2015-12-15 | 2020-07-29 | ギリアード サイエンシーズ, インコーポレイテッド | ヒト免疫不全ウイルス中和抗体 |
| EP3433269B1 (en) * | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| JP7267914B2 (ja) | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Bcma及びcd3に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| RU2665790C1 (ru) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
| US20200093789A1 (en) | 2017-05-10 | 2020-03-26 | The General Hospital Corporation | Cancer Treatment with a CXCL12 Signaling Inhibitor and an Immune Checkpoint Inhibitor |
| EP3626266A4 (en) * | 2017-05-16 | 2021-04-07 | Jiangsu Hengrui Medicine Co., Ltd. | CTLA4 ANTIBODY PHARMACEUTICAL COMPOSITION AND USES THEREOF |
| US20200140547A1 (en) * | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| GB201709808D0 (en) * | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| AR112257A1 (es) * | 2017-06-21 | 2019-10-09 | Gilead Sciences Inc | Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos |
| EP3908664A4 (en) | 2019-01-07 | 2023-01-25 | Thomas Jefferson University | MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
-
2020
- 2020-01-07 EP EP20738361.3A patent/EP3908664A4/en active Pending
- 2020-01-07 JP JP2021539880A patent/JP7587505B2/ja active Active
- 2020-01-07 MX MX2021008207A patent/MX2021008207A/es unknown
- 2020-01-07 WO PCT/US2020/012624 patent/WO2020146423A1/en not_active Ceased
- 2020-01-07 CA CA3125748A patent/CA3125748A1/en active Pending
- 2020-01-07 AU AU2020207265A patent/AU2020207265B2/en active Active
- 2020-01-07 BR BR112021013415A patent/BR112021013415A2/pt unknown
- 2020-01-07 US US17/421,053 patent/US12497439B2/en active Active
- 2020-01-07 SG SG11202107454UA patent/SG11202107454UA/en unknown
- 2020-01-07 CN CN202080016520.5A patent/CN113518823B/zh active Active
- 2020-01-07 KR KR1020217024898A patent/KR20220025698A/ko active Pending
-
2021
- 2021-07-07 IL IL284679A patent/IL284679A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220025698A (ko) | 2022-03-03 |
| CN113518823A (zh) | 2021-10-19 |
| US12497439B2 (en) | 2025-12-16 |
| AU2020207265A1 (en) | 2021-08-12 |
| EP3908664A4 (en) | 2023-01-25 |
| US20220056102A1 (en) | 2022-02-24 |
| CA3125748A1 (en) | 2020-07-16 |
| JP2022528030A (ja) | 2022-06-08 |
| CN113518823B (zh) | 2025-05-02 |
| EP3908664A1 (en) | 2021-11-17 |
| BR112021013415A2 (pt) | 2021-12-28 |
| AU2020207265B2 (en) | 2026-03-26 |
| WO2020146423A1 (en) | 2020-07-16 |
| SG11202107454UA (en) | 2021-08-30 |
| JP7587505B2 (ja) | 2024-11-20 |
| MX2021008207A (es) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284679A (en) | Multifunctional chimeric proteins and their use | |
| IL279510A (en) | Progranulin-FC polypeptide fusion proteins and their uses | |
| IL279505A (en) | Chimeric transmembrane protein and its uses | |
| EP3743438A4 (en) | CYTOKI FUSION PROTEINS | |
| EP3287470A4 (en) | Novel recombinant bi-functional fusion protein and preparation and application therefor | |
| ZA201808284B (en) | Gdf15 fusion proteins and uses thereof | |
| SG11202012004SA (en) | Rna-targeting fusion protein compositions and methods for use | |
| SI3628049T1 (sl) | Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba | |
| SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
| IL278102A (en) | Fusion proteins containing cd47 antibodies and cytokines | |
| SG11202104912SA (en) | Fusion protein and use thereof | |
| GB2570063B (en) | Fusion protein and applications thereof | |
| EP3836959A4 (en) | ANTI-ANGIOGENESIS FUSION PROTEIN AND USES ITS | |
| EP3863657A4 (en) | BIFUNCTIONAL FUSION PROTEINS AND USES THEREOF | |
| ZA202003845B (en) | Fusion proteins | |
| IL279057A (en) | Antimicrobial fusion proteins containing endolysin and their uses | |
| IL273626A (en) | Immunomodulatory fusion proteins | |
| GB201816873D0 (en) | Fusion protein | |
| GB202201003D0 (en) | Fusion polypeptide and use thereof | |
| IL286799A (en) | Consolidated structures and their uses | |
| GB202201004D0 (en) | Reconbinant fusion polypeptide and use thereof | |
| EP4423260A4 (en) | Truncated and fusion proteins | |
| AU2017305946A8 (en) | C1q and HMGB1 fusion proteins and uses thereof | |
| GB202105044D0 (en) | Fusion protein | |
| EP3307304A4 (en) | Immunoglobulin fusion proteins and uses thereof |